Ipca Laboratories Ltd
Ipca Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.
From Ipca Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms.
- Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth.
- Unichem, a subsidiary, is expected to grow around 10% in the current financial year.
- U.S. business showed a 14% growth in FY26; continued growth is anticipated next year.
- CIS market expected to grow around 10%-11%; domestic India market around 12%-13%.
- Generic business including U.S. and Europe expected to grow around 12%-13%.
- Launches planned: Ipca to commercialize 6-8 products in FY27; Unichem to launch 5-6 products.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any specific current or future capex or capital investments.
- There is mention of a U.S. formulation facility under construction at Pisgah Labs, expected to be commissioned by Q4 of the current financial year, with meaningful turnover from this plant anticipated only in the next financial year.
- No other strategic investments or capital expenditure plans are detailed in the provided transcript.
- The focus appears to be on product launches and expanding manufacturing capabilities (including shifting production from Ireland back to India for Unichem), which may imply ongoing capital spending but no explicit capex numbers or plans are disclosed.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Ipca Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.4K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Labs.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Ipca Laboratories Ltd Q4 FY26 results?
Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.
What is Ipca Laboratories Ltd share price analysis?
Ipca Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 32.0 with a market cap of ₹43,997 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Laboratories Ltd planning capital expenditure?
The transcript does not explicitly mention any specific current or future capex or capital investments. - There is mention of a U.S.
Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.